Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 158

Results For "MP"

9962 News Found

Mumbai doctors perform India’s first robotic surgery to fix rare uterine defect in 23 year old
Hospitals | March 10, 2026

Mumbai doctors perform India’s first robotic surgery to fix rare uterine defect in 23 year old

Doctors recommended a robotic Strassmann Metroplasty, a reconstructive surgery that joins the two halves of the uterus into a single cavity capable of supporting pregnancy


Avio Smart teams up with Huwel Lifesciences to roll out next-gen molecular diagnostics in India
News | March 10, 2026

Avio Smart teams up with Huwel Lifesciences to roll out next-gen molecular diagnostics in India

Huwel’s diagnostic solutions leverage open RT-PCR system


FDA nod to Bristol Myers Squibb’s Sotyktu as new oral therapy for psoriatic arthritis
Drug Approval | March 10, 2026

FDA nod to Bristol Myers Squibb’s Sotyktu as new oral therapy for psoriatic arthritis

The FDA decision was based on results from the pivotal POETYK PsA-1 and POETYK PsA-2 Phase 3 trials


AbbVie reports promising early results for novel obesity therapy ABBV-295
News | March 10, 2026

AbbVie reports promising early results for novel obesity therapy ABBV-295

ABBV-295 produced clinically meaningful, dose-dependent weight loss over 12–13 weeks


Bristol Myers Squibb reports positive phase 3 results for oral multiple myeloma therapy
Clinical Trials | March 10, 2026

Bristol Myers Squibb reports positive phase 3 results for oral multiple myeloma therapy

The interim results of the Phase 3 SUCCESSOR-2 study's safety profile aligned with expectations for both mezigdomide and the combination regimen


Sumitomo Pharma bags world-first go-ahead for iPS cell therapy to treat Parkinson’s disease
News | March 10, 2026

Sumitomo Pharma bags world-first go-ahead for iPS cell therapy to treat Parkinson’s disease

The conditional, time-limited approval comes through a joint effort with RACTHERA, a joint venture in which Sumitomo Chemical holds a 66.6% stake and Sumitomo Pharma holds 33.4%


FDA grants priority review to Enhertu for high-risk HER2-positive breast cancer
News | March 10, 2026

FDA grants priority review to Enhertu for high-risk HER2-positive breast cancer

Enhertu recently received Breakthrough Therapy Designation, accelerating development and review for this critical patient population


SEQSTER launches 1-Click DataLake, unlocking real-world health data from 150M+ patients
Digitisation | March 09, 2026

SEQSTER launches 1-Click DataLake, unlocking real-world health data from 150M+ patients

The company says those insights can power advanced analytics and real-world evidence (RWE), helping researchers improve trial design, study feasibility, and recruitment strategies


Lupin receives two observations from USFDA for Ankleshwar facility
Drug Approval | March 09, 2026

Lupin receives two observations from USFDA for Ankleshwar facility

The company will address the observations and respond to the U.S. FDA within the stipulated timeframe